Skip to main content
Nephrology Dialysis Transplantation logoLink to Nephrology Dialysis Transplantation
. 2018 May 11;33(7):1280. doi: 10.1093/ndt/gfy135

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

Claire C J Dekkers, David C Wheeler, C David Sjöström, Bergur V Stefansson, Valerie Cain, Hiddo J L Heerspink
PMCID: PMC6031052  PMID: 29762740

Nephrology Dialysis Transplantation, gfx350, https://doi.org/10.1093/ndt/gfx350

In the above article, the n numbers for the least squares mean values (LSM) reported below figure 2A were incorrect. The numbers for Week 102 were repeated under the graph rather than displaying the true LSM values, which were 62 for placebo, 55 for dapagliflozin 5 mg and 85 for dapagliflozin 10 mg. The authors apologise for the error which has been corrected.


Articles from Nephrology Dialysis Transplantation are provided here courtesy of Oxford University Press

RESOURCES